Advertisement

COVID-19 Federal Responses: Thursday, May 5, 2022

COVID-19 Federal Responses: Thursday, May 5, 2022
  • New research about the cognitive impairment effects of long COVID-19 compares these symptoms to 20 years of cognitive aging and a reduction of 10 IQ points.
  • COVID-19 is becoming increasingly comparable to the flu as we learn more about the virus and develop effective vaccines and treatments.
  • FDA leaders wrote an Op-Ed expressing their belief that annual COVID-19 booster doses will be required.
  • New sub-variants of the Omicron variant are causing increased cases of COVID-19.

White House and Federal Agencies

  • The Administration is experiencing several challenges with its effort to increase awareness and access to Pfizer’s Paxlovid COVID-19 antiviral treatment.

Economy, Vaccines, Testing and Treatment

  • FDA leaders wrote an Op-Ed expressing their belief that annual COVID-19 booster doses will be required.
  • New sub-variants of the Omicron variant are causing increased cases of COVID-19.
  • The FDA is disputing a claim from Pfizer’s CEO that a second dose of its Paxlovid COVID-19 antiviral treatment will prevent patients from experiencing symptoms if they are re-infected with COVID-19.
    • Also, in rare cases, patients are reporting renewed symptoms after finishing their course of Paxlovid.
  • COVID-19 is becoming increasingly comparable to the flu as we learn more about the virus and develop effective vaccines and treatments.
  • New research about the cognitive impairment effects of long COVID-19 compares these symptoms to 20 years of cognitive aging and a reduction of 10 IQ points.
  • The official U.S. death toll from COVID-19 reached 1 million.

 

Advertisement